Clinical Roundup Enhertu reduced the risk of disease recurrence or death vs. T-DM1 in high-risk HER2+ early breast cancer following neoadjuvant therapy October 24, 2025Vol.51 No.39
Clinical Roundup Enhertu + THP before surgery resulted in a pathologic complete response in high-risk HER2+ early-stage breast cancer October 24, 2025Vol.51 No.39
Clinical Roundup Keytruda + Padcev reduced risk of EFS events and death for muscle-invasive bladder cancer when given before and after surgery October 24, 2025Vol.51 No.39
Clinical Roundup Verzenio delivers OS benefit in high-risk early breast cancer October 24, 2025Vol.51 No.39
Clinical Roundup Imfinzi regimen reduced the risk of disease recurrence or death by 32% in high-risk non-muscle-invasive bladder cancer October 24, 2025Vol.51 No.39
Clinical Roundup Imfinzi-based regimen reduced the risk of death in early gastric cancer vs. chemotherapy alone October 24, 2025Vol.51 No.39
Clinical Roundup Tecvayli + Darzalex Faspro improve PFS and OS vs. standard-of-care October 24, 2025Vol.51 No.39
Clinical Roundup GammaTile delivers superior tumor control vs. standard-of-care for newly diagnosed operable brain metastases October 24, 2025Vol.51 No.39
Clinical Roundup Enzalutamide drug combination cuts risk of death in advanced prostate cancer, Cedars-Sinai-led study shows October 24, 2025Vol.51 No.39
